■纳米脉冲刺激(NPS)疗法在纳秒域中施加电脉冲,以启动受治疗组织中的调节细胞死亡。这种非热疗法已被用于治疗广泛的鼠类肿瘤,并已被证明可以激活免疫系统以抑制再攻击肿瘤的生长,以及未经处理的,当伴随着免疫系统刺激物注射到治疗的肿瘤时,腹腔镜肿瘤。临床试验已经开始使用NPS治疗基底细胞癌和肝细胞癌。
■当皮内注射肿瘤细胞以使其在小鼠皮肤内生长时,可以容易地对小鼠肿瘤进行成像。在半透明的光柱上拉动皮肤使光通过皮肤发光,并且使得容易治疗肿瘤和识别治疗区域。
■描述了使用小鼠肿瘤模型的原始研究,包括黑色素瘤,鳞状细胞癌,肺癌,乳腺癌,和胰腺癌.已经确定了消融这些肿瘤所需的能量,胰腺癌和肺癌显示出90%消融,240mJ/mm3,肺癌和鳞状细胞癌需要360mJ/mm3,黑色素瘤需要480mJ/mm3。NPS疗法引发了可变的免疫反应,通过注射的再攻击肿瘤细胞的排斥反应表明,黑色素瘤和肝细胞癌表现出最强的反应和肺癌,最弱的反应。根据原始研究数据,综述了使用NPS治疗的人体临床试验.
■NPS治疗提供了一种非热,肿瘤学的无药方法,这只能通过向肿瘤施加能量来限制。这种新的免疫原性方式刚刚开始在临床上应用。数名医务人员进行的首次大型临床试验的87%疗效令人印象深刻,表明NPS是癌症治疗的有效新方式。
UNASSIGNED: Nano-Pulse Stimulation (NPS) therapy applies electric pulses in the nanosecond domain to initiate regulated cell death in the treated tissues. This nonthermal therapy has been used to treat a wide range of murine tumors and has been shown to activate the immune system to inhibit the growth of rechallenge tumors, as well as untreated, abscopal tumors when accompanied by the injection of immune system stimulants into the treated tumors. Clinical trials have begun using NPS to treat basal cell carcinoma and hepatocellular carcinoma.
UNASSIGNED: Murine tumors can be easily imaged when the tumor cells are injected intradermally so that they grow within the mouse skin. Pulling the skin over a translucent light post shines light through the skin and makes it easy to treat the tumor and identify the treatment zone.
UNASSIGNED: Original research using murine tumor models is described, including melanoma, squamous cell carcinoma, lung carcinoma, breast carcinoma, and pancreatic carcinoma. The energy required to ablate these tumors has been determined with pancreatic carcinoma and lung carcinoma exhibiting 90% ablation with 240 mJ/mm3, lung carcinoma and squamous cell carcinoma requiring 360 mJ/mm3, and melanoma requiring 480 mJ/mm3. NPS therapy initiated a variable immune response indicated by the rejection of injected rechallenge tumor cells with melanoma and hepatocellular carcinoma exhibiting the strongest response and lung carcinoma, the weakest response. Following the original research data, a review of human clinical trials using NPS therapy is presented.
UNASSIGNED: NPS therapy offers a nonthermal, drug-free approach for oncology, which is limited only by applying energy to the tumor. This new immunogenic modality is just beginning to be applied in the clinic. The 87% efficacy of the first large clinical trial conducted by several medical personnel is impressive and indicates that NPS is an effective new modality for cancer treatment.